QualityStocksNewsBreaks – Soligenix, Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics
Soligenix (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial highlighting its progress in addressing rare diseases, particularly among aging populations. The piece emphasizes the urgent need for effective treatments as over 30 million Americans live with rare conditions, many lacking FDA-approved therapies. Soligenix’s HyBryte(TM) platform, targeting cutaneous T-cell lymphoma—a rare skin cancer affecting older adults—represents a promising solution. With successful domestic manufacturing of HyBryte’s active ingredient, the company advances its mission to serve this underserved demographic with innovative, U.S.-based therapies. To view the full press release, visit https://ibn.fm/NfPBX About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on…